IntroductionLack of confidence in intra-articular hyaluronic acid injections for osteoarthritis (OA) may result from conflicting guidelines and pooling of results for different molecular weight products. ObjectivesThe objectives were to determine responder rates to injections of very-high-molecular-weight hyaluronic acid (VHMW-HA) vs high-molecular-weight hyaluronic acid (HMW-HA) for knee OA and treatment efficacy measured by the interval between follow-up injections. MethodsA retrospective analysis of a 15-year cohort from a single center. Inclusion criteria: adults with Kellgren-Lawrence Grade III or IV knee OA treated with hyaluronic acid injections. Subjects were stratified into 2 groups based on the molecular weight of the hyaluronic acid. Outcome measures were responder rates with improvement in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores of >30% from baseline vs nonresponders; those with a response lasting >6 months after each injection were considered sustained responders. ResultsIn total, 2037 (female 1467 [72.02%] and male 570 [27.98%]) patients were treated. The overall primary responder rate was 73.44% (1496). VHMW-HA had significantly higher primary responders (75.21% vs 70.22%, P = .015) and significantly lower nonresponders (24.79% vs 29.78%, P = .015). As a subset of primary responders, the sustained responders had greater responses with VHMW-HA vs HMW-HA (85.54% vs 67.06%, P < .0001) and lower dropouts (14.46% vs 32.94%, P < .0001). The average interval between the first and the third injections was longer for VHMW-HA vs HMW-HA—5.67 vs 1.95 years (P < .0001). ConclusionsAbout 73.44% of subjects responded to treatment with intra-articular hyaluronic acid. The sustained response was greater in VHMW-HA vs HMW-HA and VHMW-HA has a longer duration of effect than HMW-HA.
Read full abstract